Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.
The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.
Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.
Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.
In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.
- Location: Boulder, Colorado
- Core Focus: Novel therapies for rare muscle disorders
- Key Projects: Orally bioavailable small molecule therapies
- Partnerships: Supported by OrbiMed and other strategic investors
Edgewise Therapeutics (NASDAQ: EWTX) has appointed Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox, currently President and CMO at BridgeBio Pharma and former CMO at MyoKardia, brings extensive experience in cardiovascular clinical development. His expertise will support Edgewise's advancement of EDG-7500, a novel therapy for hypertrophic cardiomyopathy, with a Phase 1 trial expected in late 2023. Dr. Fox's background includes pivotal roles in the development of Camzyos® (mavacamten), emphasizing his capability to boost Edgewise's leadership in cardiovascular therapies.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:10 am ET. The presentation will be webcast live, with a replay available afterward. Edgewise focuses on developing small molecule therapies for muscle disorders, including its lead candidate, EDG-5506, which targets dystrophinopathies. The company is also advancing EDG-7500 for hypertrophic cardiomyopathy. Further details can be found on their website.
Edgewise Therapeutics (NASDAQ: EWTX) announced the presentation of EDG-7500, a first-in-class oral therapy for hypertrophic cardiomyopathy (HCM), at the American College of Cardiology's 72nd Annual Scientific Session on March 5, 2023. This investigational drug aims to normalize excess cardiac contraction and improve impaired relaxation, addressing both obstructive and non-obstructive HCM. Key findings include significant improvements in cardiovascular pathophysiologies and potent gradient reductions. The company plans to initiate a Phase 1 trial for EDG-7500 in late 2023, supporting further clinical development based on promising preclinical data.
Edgewise Therapeutics (NASDAQ: EWTX) announced significant advancements in clinical trials for EDG-5506 targeting muscular dystrophies. Phase 2 trials for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) have shown promising developments, with interim data expected in late 2023. The company also initiated IND-enabling studies for EDG-7500, a new treatment for hypertrophic cardiomyopathy, set to begin Phase 1 trials in the second half of 2023. As of December 31, 2022, Edgewise reported cash and marketable securities totaling
Edgewise Therapeutics (EWTX), a clinical-stage biopharmaceutical company, announced its participation in the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 pm ET. The presentation will be streamed live with a replay available afterward. Edgewise focuses on developing innovative treatments for severe neuromuscular and cardiac disorders, with its lead candidate, EDG-5506, in clinical trials for various muscular dystrophies. Additionally, the company is progressing EDG-7500, a novel treatment for hypertrophic cardiomyopathy. For more details, visit Edgewise's website.
Edgewise Therapeutics (NASDAQ: EWTX) announced its participation in the J.P. Morgan 41st Annual Healthcare Conference on January 10, 2023, at 9:45 am PT (12:45 pm ET). The presentation will be available via a live webcast, with a replay option post-event. Edgewise focuses on developing targeted therapies for severe muscle disorders, including its lead candidate, EDG-5506, aimed at treating Duchenne muscular dystrophy. The company is advancing another candidate, EDG-7500, for hypertrophic cardiomyopathy in preclinical development.
Edgewise Therapeutics (NASDAQ: EWTX) announced plans for a virtual investor call on January 3, 2023, showcasing preclinical data for its lead candidate, EDG-7500, targeting hypertrophic cardiomyopathy (HCM). Commentary will be provided by a leading cardiologist. CEO Kevin Koch stated that the preclinical data could address unmet needs in HCM treatment, with an IND application expected in the second half of 2023. Additionally, the company will present its 2023 outlook at the J.P. Morgan Healthcare Conference on January 10, 2023.
Edgewise Therapeutics (NASDAQ: EWTX) announces the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran, with extensive experience in clinical development, previously served as CMO at Renovacor and MyoKardia, leading to their acquisitions. He will guide Edgewise's cardiovascular program, aiming for an IND filing in the latter half of 2023. Dr. Semigran's expertise includes overseeing successful drug development projects, notably mavacamten for hypertrophic cardiomyopathy.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The Stifel 2022 Healthcare Conference will take place on
Edgewise Therapeutics reported promising 6-month interim results for EDG-5506 in Becker muscular dystrophy (BMD), showing significant decreases in biomarkers of muscle damage (39% for creatine kinase, 75% for fast skeletal muscle troponin I). With a robust cash position of
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
What is Edgewise Therapeutics, Inc.?
Where is Edgewise Therapeutics located?
What is the core focus of Edgewise Therapeutics?
What are Edgewise Therapeutics' key projects?
Who financed Edgewise Therapeutics' Series A round?
Is Edgewise Therapeutics a public company?
What recent achievements has Edgewise Therapeutics made?
What kind of diseases is Edgewise Therapeutics targeting?
What type of therapies is Edgewise Therapeutics developing?
What makes Edgewise Therapeutics' treatments innovative?
